$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

An efficacy test of PRP (polyribosylribitol phosphate)-TT (Tetanus toxoid) conjugate vaccines was carried out using BALB/c mice as an animal model by inoculating Haemophilus in­fluenzae type b (Hib) with a virulence enhancement factor (VEF). Three administrations of the conjugate vaccines at 2-week intervals elicited a significantly high level of PRP antibodies (P>0.0001). The protective activity of the PRP immunization was challenged with either Hib with iron dextran (Hib/) or with a combination of mucin and hemoglobin (Hibmh) as a VEF. The me­dium lethal dose $(LD_{50})$ for Hibmh and Hibiwas measured as 10 CFU (Colony Forming Unit) and $2.5{\times}10^{8}$ CFU respectively. Each immunized animal was challenged with five or ten times the $LD_{50}$ level of bacteria with a VEF. A significant difference in mortality between the immunized and control mice (P> 0.01) was observed with the Hibmh challenge inoculation but not with the Hibi challenge inoculation. These results show that a combination of mucin and hemoglobin was able to enhance the virulence of Hib in BALB/c mice to cause a lethal infection, thus suggesting that BALB/c mice introduced to this method can be an effective model animal for testing the protective efficacy of H. influenzae conjugate vaccines.

참고문헌 (28)

  1. Coulehan, J. L., R. H. Michaels, K. E. Williams, D. K. Lemley, C. Q. Jr. North, T. K. Welty, and K. D. Rogers (1976) Bacterial meningitis in Navajo indians. Public Health Rep. 91: 464-468 
  2. Immunization practices advisory (ACIP) (1986) Update: Prevention of Haemophilus influenzae type b disease. Morbid. Mortal. Week. Rep. 35: 170 
  3. Heath, P. T. and M. Fracp (1998) Haemophilus influenzae type b conjugate vaccines: A review of efficacy data. Pediatr. Infect. Dis. J. 17: S117-122 
  4. Burans, J. P., F. H. Kruszeski, M. Lynn, and M. Solotrovsky (1981) Kinetics of Haemophilus influenzae type b infection in normal and ribosom-immunized mice using intraperitoneal and intracerebral routes of inoculation. Br. J. Exp. Pathol. 62: 496-503 
  5. Kristensen, K, and M. W. Bentzon (1992) Relation be-tween enzyme-linked immunoserbent assay and radioim-munoassay for detection of antibodies to the capsular polysaccharide of Haemophilus influenzae type b. APMIS 100: 142-146 
  6. Miller, C. P. (1933) Experimental meningococcal infection of mice. Science 78: 340-341 
  7. Cochi, S. L., C. V. Broome, and A. W. Hightower (1985) Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine. J. Am. Med. Ass. 253: 521-529 
  8. Pittman M. (1933) The action of type-specific H. influenzae antiserum. J. Exp. Med. 58: 683-706 
  9. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. (1993) Morb. Mortal. Wkly. Rep. 42: 296-298 
  10. Onodera, M. (2002) Silicone rubber membrane bioreactors for bacterial cellulose production. Biotechnol. Bioprocess Eng. 10: 289-294 
  11. Moxon, E. R., A. L. Smith, D. R. Averill, and D. H. Smith (1974) Haemophilus influenzae meningitis in infant rats after intranasal inoculation. J. Infect. Dis. 129: 154-162 
  12. Kuo, J. S. C., N. Monji, R. S. Schwalbe, and D. W. McCoy (1981) A radioactive antigen-binding assay for the meas-urement of antibody to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. Methods 43: 35-47 
  13. Granoff, D. M. (2001) Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin. Infect. Dis. 33: S278-287 
  14. Tarr, P. I. and G. Peter (1978) Demographic factors in the epidemiology of Haemophilus influenzae meningitis in young children. J. Pediat. 92: 884-888 
  15. Kaplan, S. L., E. O. Mason, Jr., and B. L. Wiedermann (1983) Role of adherence in the pathogenesis of Haemophilus influenzae type b infection in infant rats. Infec. Immun. 42: 612-617 
  16. Brodeur, B. R., P. S. Tsang, J. Hamel, Y. Larose, and S. Montplaisir (1986) Mouse models of infection for Neisseria meningitides B, 2b and Haemophilus influenzae type b diseases. Can. J. Microbiol. 32: 33-37 
  17. Ward. J. (1991) Prevention of invasive Haemophilus influenzae type b disease: Lessons from vaccine efficacy trials. Vaccine 9: S17-24 
  18. Warlaw, A. C. (1985) Practical Statistics for Experimental Biologists. JohnWiley Wiley & Sons Ltd, USA 
  19. Smith, A. L., D. H. Smith, D. R. Averill, Jr., J. Marino, and E. R. Moxon (1983) Haemophilus influenzae type b bacteremia and meningitis infant rabbits after intranasal inoculation. J. Lab. Clin. Med. 102: 939-946 
  20. Halesy, N. A., T. L. Johansen, L. C. Bowman, and M. P. Glode (1983) Evaluation of the protective efficacy of Haemophilus influenzae type b vaccines in an animal model. Infec. Immun. 39: 1196-1200 
  21. Broueur, B. R., Y. Larose, P. Tsang, J. Hamel, F. Ashton, and A. Ryan (1985) Protection against infection with Neisseria meningitides group B serotype 2b by passive immunization with serotype specific monoclonal antibody. Infect. Immun. 50: 510-516 
  22. Corbeil, G. A., C. P. Kenny, and G. Laverne (1976) Iron as a replacement for mucin in the establishment of meningococcal infection in mice. Can. J. Microbiol. 22: 832-838 
  23. Marks, M. I., E. J. Ziegler, H. Douglas, and L. B. Corbeil (1982) Lethal Haemophilus influenzae type b infection in mice. Infection 10: 261-266 
  24. Rodriguez, S. S., J. F. I. Bourzac, O. M. Chang, M. F. Medina, E. M. Carnago, and Y. L. Hernandez (1999) Virulence enhancement agents for Haemophilus influenzae type b infection in mice. Lab. Anim. Sci. 49: 95-98 
  25. Farr, R. S. (1958) A quantitative immunochemical measurement of the primary interaction between I*BSA and antibody. J. Infect. Dis. 103: 239-262 
  26. Frasch, C. E. (1994) Regulatory perspectives in vaccine licensure. pp.435-453. In: Ellis R. W, D. W. Granoff (eds.). Development and Clinical Uses of Haemophilus b Conjugate Vaccine. Mercel Dekkar, New York, USA 
  27. Ward, J., G. Brenneman, G. W. Leston, and W. L. Heyward (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N. Engl. J. Med. 323: 1391-1401. 
  28. Hong, H. J. and S. T. Kim (2002) Antibody engineering. Biotechnol. Bioprocess Eng. 7: 150-154 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일